Investors are bracing for the worst and waiting to see if Synovus
What analysts say:
- Buy, sell, or hold?: Analysts think investors should stand pat on Synovus, with 17 of 23 analysts rating it hold. Analysts don't like Synovus as much as competitor First Horizon National overall. Ten out of 24 analysts rate First Horizon National a buy compared with four of 23 for Synovus. While analysts still rate the stock a hold, they are a little more optimistic about it compared with three months ago.
- Revenue forecasts: On average, analysts predict $303.6 million in revenue this quarter. That would represent a decline of 6.3% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is a loss of $0.06 per share. Estimates range from a loss of $0.12 to a loss of $0.02.
What our community says:
CAPS All-Stars are solidly behind the stock, with 86.8% awarding it an "outperform" rating. The community at large agrees with the All-Stars, with 86.3% granting it a rating of "outperform." Fools are keen on Synovus and haven't been shy with their opinions lately, logging 179 posts in the past 30 days. Despite the majority sentiment in favor of Synovus, the stock has a middling CAPS rating of three out of five stars.
Revenue has fallen for the past three quarters.
For all our Synovus-specific analysis, including earnings and beyond, add Synovus to My Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.